When: RSI bullish divergence at oversold levels

Then: Second confirmation for re-engagement (one of two required)

When: Forward EPS reaffirmation at $6.00+ with Nutrition stabilization

Then: Second confirmation for re-engagement (one of two required)

Reduce to 50% target weight, tighten stop to $99.50, do not add until confirmed bullish signals, exit entirely if Q3 earnings disappoint

• VWMA above price ($1.49 spread) indicates institutional selling, not accumulation
• RSI at 35.25 is not oversold (threshold is below 30); MACD histogram at negative 0.33 is expanding, showing firming downside momentum
• Death cross forming: 50 SMA has crossed above 200 SMA for first time in 12 months
• Relevant downside is $17.23 to the 52-week low at $83.72, not $2.87 to $98.08, making R/R roughly 1:0.7 against rather than 1:4 in favor
• Forward P/E of 16.64 may be revised downward given $20 billion M&A integration risk; trailing P/E of 32.67 reflects current integration drag
• 48% of total assets as goodwill with negative tangible book value leaves no margin of safety; 10% acquisition underperformance creates $5 billion impairment risk
• 30-year Treasury at highest level since 2002, mortgage rates at 7.58%, gold at $4,147 (fear bid not safe-haven), recession odds on Polymarket trending higher
• Low retail/ institutional interest is neglect, not accumulation; neglected names drift lower until forced re-rating
• Stop-loss at $98.08 fails in Q3 earnings gap scenarios; miss could cause $5-8+ gap to $93 or $88
• Conservative analyst recommends 50% target weight (vs aggressive 75%), stop at $99.50 (vs $98.08), no additions until $102.27 close above 10 EMA on volume above VWMA OR RSI below 30 with bullish reversal
• Treat Q3 earnings as mandatory exit trigger on any softness, guidance disappointment, or impairment commentary

→ vs aggressive: The VWMA above price ($102.44 vs $100.95) confirms institutional selling, not accumulation as claimed. When institutions accumulate, price sits above VWMA or VWMA migrates toward price.

→ vs aggressive: RSI at 35.25 is not capitulation; oversold requires RSI below 30. In strong downtrends, RSI can sit in the 30s for weeks.

→ vs aggressive: The death cross (50 SMA crossing above 200 SMA) is a structural bearish event, not a pattern to dismiss.

→ vs aggressive: The $2.87 downside to $98.08 is not the relevant risk. The true downside is $17.23 to the 52-week low at $83.72, reframing R/R from 1:4 to approximately 1:0.7 against.

→ vs aggressive: Forward P/E of 16.64 is not a value opportunity; it reflects the market pricing in meaningful probability that the $6.07 forward EPS estimate will be revised downward due to M&A integration drag.

→ vs aggressive: Every goodwill impairment in medical devices in the last decade (Medtronic, Zimmer Biomet, Boston Scientific) was defended as 'strategic' at announcement and became an impairment within 24 months. No impairment in 6 months is not evidence it won't happen.

→ vs aggressive: Gold at $4,147 with long-end yields rising is a fear bid, not a safe-haven bid; ABT's 0.586 beta means it underperforms cyclicals but still falls in a true liquidity crisis.

→ vs aggressive: Low retail interest in a defensive healthcare name is baseline normal, not evidence of accumulation. It represents neglect, not quiet positioning.

→ vs aggressive: The stop at $98.08 assumes normal fill conditions. In a Q3 earnings gap scenario, Abbott could open at $93, $88, or worse on a miss or impairment announcement, making the stop unreliable.

→ vs aggressive: Paying 3% for confirmation is not slippage - it is insurance against a 15-25% drawdown if the stock breaks the May low at $83.72. The cost of patience is a 5-to-1 favorable tradeoff.

HOLD at 75% sizing with stop at $98.08; pre-earnings trim to ~55%; redeploy on reclaim of $103.97 on volume

• Forward P/E of 16.64 with $6.07 EPS estimate is attractive; goodwill at 48% of assets is a tail risk, not base case
• Confirmed downtrend: death cross forming, multi-MA bearish stack, expanding MACD histogram, lower-high sequence, price at lower Bollinger Band ($98.08)
• Defensive rotation tailwind real but not immune to broader risk-off; beta of 0.586 means meaningful drawdown in severe correction
• 75% sizing is well-calibrated: not too aggressive nor too conservative for this setup
• Stop at $98.08 (lower Bollinger Band) is structural support; tightening to $99.50 would exit on noise with ATR at $2.23
• Pre-earnings trim to ~55% addresses gap risk surgically rather than wholesale position reduction
• Re-engagement trigger: reclaim of Bollinger midline ($103.97) on volume confirms upside
• Do not add on weakness before Q3 catalyst resolves; confirmed downtrend requires confirmation before re-engaging incremental capital

→ vs aggressive: VWMA above price is selling confirmation, not stealth accumulation; price drifting below VWMA on declining volume is neglect, not institutional stepping in—removes empirical foundation from bullish case

→ vs conservative: Tightening stop to $99.50 would sit 65 cents below current price with ATR of $2.23, triggering exit on routine down day before $98.08 support is even tested—exiting on noise rather than structural break

→ vs conservative: Tightening stop doesn't fix gap risk around earnings; the correct response is position sizing and pre-earnings de-risking, not stop placement changes

→ vs aggressive: Solving for opportunity while ignoring probability; adding on flush to $98 ignores confirmed downtrend with binary catalyst ahead

→ vs conservative: Solving for probability while ignoring opportunity; both treating this as binary rather than portfolio construction question